Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 77
Filtrar
1.
Clin Neurol Neurosurg ; 160: 125-129, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28727995

RESUMO

OBJECTIVES: Patients with Amyotrophic Lateral Sclerosis (ALS) have expressed desire to become living organ donors but are unable to do so with current organ donation policies. Our objective is to assess ALS patient's interest in organ donation, and perceived concerns of this practice by ALS neurologists. PATIENTS AND METHODS: An electronic survey was administered to ALS neurologists across the United States regarding living organ donation in ALS patients prior to respiratory failure. RESULTS: 52 complete responses were received from 121 invites. 67% (35/52) of neurologists expressed no concerns about living organ donation in ALS patients, and 33% had concerns. The concerns related to respiratory failure, anesthesia exposure and renal dysfunction. With their concerns addressed, 71% of neurologists reported that they would endorse living organ donation. 49% of neurologists reported being asked by a patient for information regarding living organ donation. ALS neurologists felt that 22.8% of ALS patients (median 19%) would be interested in learning more about organ donation, while only 6% of neurologists broach this subject with their patients. CONCLUSION: Our results indicate that 1 in every 4 ALS patients may be interested in exploring options for living organ donation, and this topic is not routinely addressed by ALS clinics. These results indicate an unexplored area of patient interest. To honor a patient's wishes to donate, the transplant community will have to accommodate living organ donation from terminally ill patients, and address neurologist concerns. Such a practice could benefit two groups of patients.


Assuntos
Esclerose Lateral Amiotrófica , Atitude do Pessoal de Saúde , Neurologistas/estatística & dados numéricos , Doadores de Tecidos/estatística & dados numéricos , Obtenção de Tecidos e Órgãos/estatística & dados numéricos , Humanos , Estados Unidos
2.
Neurology ; 77(10): 973-9, 2011 Sep 06.
Artigo em Inglês | MEDLINE | ID: mdl-21813790

RESUMO

OBJECTIVE: To use a historical placebo control design to determine whether lithium carbonate slows progression of amyotrophic lateral sclerosis (ALS). METHODS: A phase II trial was conducted at 10 sites in the Western ALS Study Group using similar dosages (300-450 mg/day), target blood levels (0.3-0.8 mEq/L), outcome measures, and trial duration (13 months) as the positive trial. However, taking riluzole was not a requirement for study entry. Placebo outcomes in patients matched for baseline features from a large database of recent clinical trials, showing stable rates of decline over the past 9 years, were used as historical controls. RESULTS: The mean rate of decline of the ALS Functional Rating Scale-Revised was greater in 107 patients taking lithium carbonate (-1.20/month, 95% confidence interval [CI] -1.41 to -0.98) than that in 249 control patients (-1.01/month, 95% CI -1.11 to -0.92, p = 0.04). There were no differences in secondary outcome measures (forced vital capacity, time to failure, and quality of life), but there were more adverse events in the treated group. CONCLUSIONS: The lack of therapeutic benefit and safety concerns, taken together with similar results from 2 other recent trials, weighs against the use of lithium carbonate in patients with ALS. The absence of drift over time and the availability of a large database of patients for selecting a matched historical control group suggest that use of historical controls may result in more efficient phase II trials for screening putative ALS therapeutic agents. CLASSIFICATION OF EVIDENCE: This study provided Class IV evidence that lithium carbonate does not slow the rate of decline of function in patients with ALS over 13 months.


Assuntos
Esclerose Lateral Amiotrófica/tratamento farmacológico , Esclerose Lateral Amiotrófica/patologia , Progressão da Doença , Carbonato de Lítio/uso terapêutico , Programas de Rastreamento , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Programas de Rastreamento/tendências , Pessoa de Meia-Idade , Projetos de Pesquisa/tendências , Adulto Jovem
3.
Neurology ; 77(7): 684-90, 2011 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-21795659

RESUMO

Major effort and expense are devoted to faculty recruitment. Subsequent direction, support, and guidance of faculty members for retention and academic advancement are often inconsistent and ineffective. Individual mentorship is widely endorsed as an important element in advancement but often does not occur or is uneven in its pragmatic benefit. We formed a Departmental Academic Advisory Committee to provide individualized advice and guidance about career development and institutional promotion, retention, and tenure procedures. To assess the effectiveness of this process, a survey was sent to faculty members. A 100% response rate was achieved. The results of the survey demonstrated high levels of acceptance by faculty members and described benefits experienced by faculty, including better understanding of promotion and tenure policies and specific actions taken to achieve professional goals. An academic advisory committee can be a valuable adjunct to individual mentorship and to meetings with department chairs to enhance faculty satisfaction and advancement of neurology faculty members.


Assuntos
Mobilidade Ocupacional , Docentes de Medicina , Mentores , Neurologia , Seleção de Pessoal , Centros Médicos Acadêmicos , Faculdades de Medicina
4.
Neurology ; 67(9): 1659-64, 2006 Nov 14.
Artigo em Inglês | MEDLINE | ID: mdl-17101900

RESUMO

BACKGROUND: There is no generally accepted instrument for measuring quality of life (QOL) in patients with ALS. Current instruments are either too heavily weighted toward strength and physical function or useful for the evaluation of individuals but of less utility in assessing large samples. OBJECTIVE: To develop and evaluate the psychometric properties of an ALS-specific QOL instrument (the ALSSQOL) that would reflect overall QOL as assessed by the patient and would be valid and reliable across large samples. METHODS: The ALSSQOL is based on the McGill Quality of Life Questionnaire (MQOL), modified by changes in format and by adding questions on religiousness and spirituality, items derived from interviews with ALS patients, and items identified from open-ended questions administered during the MQOL. The psychometric properties of the ALSSQOL were assessed by a prospective multicenter study in which participants completed the ALSSQOL, other instruments measuring overall QOL, and instruments assessing religiousness, spirituality, and psychological distress. RESULTS: A 59-item ALSSQOL was developed; 342 patients evaluated its psychometric properties. Completion time averaged 15 minutes. Forty-six items loaded on six factors. The ALSSQOL demonstrated concurrent, convergent, and discriminant validity for the overall instrument and convergent validity for its subscales. Analysis of individual items permitted insight into variables of clinical importance. CONCLUSIONS: This new ALS-specific quality of life instrument is a practical tool for the assessment of overall quality of life in individuals with ALS and appears to be valid and useful across large samples. Validation studies of a shortened version are now under way.


Assuntos
Esclerose Lateral Amiotrófica/diagnóstico , Esclerose Lateral Amiotrófica/psicologia , Avaliação da Deficiência , Transtornos Mentais/diagnóstico , Qualidade de Vida/psicologia , Inquéritos e Questionários/normas , Transtornos de Adaptação/diagnóstico , Transtornos de Adaptação/etiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Esclerose Lateral Amiotrófica/fisiopatologia , Ansiedade/diagnóstico , Ansiedade/etiologia , Progressão da Doença , Feminino , Humanos , Masculino , Casamento , Transtornos Mentais/etiologia , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Apoio Social , Estresse Psicológico/diagnóstico , Estresse Psicológico/etiologia
5.
Am J Med Genet A ; 134(3): 295-8, 2005 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-15723292

RESUMO

Mutations in the DMD gene result in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Readily available clinical tests detect only deletions of one exon or greater, which are found in approximately 60% of cases. Mutational analysis of other types of DMD mutations, such as premature stop codons and small frameshifting insertions or deletions, has historically been hampered by the large size of the gene. We have recently reported a method that allows the rapid and economical sequencing of the entire coding region of the DMD gene, and that is more sensitive than methods based on single-strand conformational polymorphism (SSCP) screening or other preliminary screening steps. Here we use single condition amplification/internal primer (SCAIP) sequencing analysis, in combination with multiplex amplifiable probe hybridization (MAPH) analysis of duplications, to report the frequency of mutations in a large cohort of unselected dystrophinopathy patients from a single clinic. Our results indicate that 7% of dystrophinopathy patients do not have coding region mutations, suggesting that intronic mutations are not uncommon. The availability of rapid and thorough mutation analysis from peripheral blood samples, along with an improved estimate of the percentage of non-coding region mutations, will be of benefit for improved genetic counseling and in identification of cohorts for clinical trials.


Assuntos
Distrofina/genética , Distrofia Muscular de Duchenne/genética , Mutação , Códon sem Sentido , Estudos de Coortes , DNA/química , DNA/genética , Análise Mutacional de DNA/métodos , Éxons/genética , Mutação da Fase de Leitura , Deleção de Genes , Duplicação Gênica , Humanos , Distrofia Muscular de Duchenne/diagnóstico , Mutagênese Insercional , Mutação de Sentido Incorreto , Fenótipo , Polimorfismo Conformacional de Fita Simples
6.
Muscle Nerve ; 24(9): 1225-8, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11494277

RESUMO

We examined records of 121 patients coded as idiopathic polyneuropathy, extracting neuropathy symptoms, electromyographic data, and diagnostic blood work. Of 89 patients screened for glucose handling, 28 demonstrated frank diabetes mellitus. Of the remaining 61 patients, 15 (25%) had impaired glucose tolerance (IGT) by American Diabetes Association criteria (serum glucose 140--200 mg/dl 2 h after a 75-g glucose load). Excluding those with diabetes mellitus, 35% of patients with neuropathic pain had IGT, more than twice the prevalence found in large, unselected population studies. No other common etiology of polyneuropathy was identified. Two-hour oral glucose tolerance test results were often abnormal, whereas fasting glucose or hemoglobin A1c was normal. Bias due to referral pattern, body weight, or genetics might affect the comparison of our polyneuropathy cohort with a broader, population-based control. However, our results corroborate an association between IGT and painful sensory polyneuropathy and link these patients syndromically to the typical painful polyneuropathy of diabetes mellitus.


Assuntos
Glicemia/metabolismo , Neuropatias Diabéticas/etiologia , Neuropatias Diabéticas/metabolismo , Neurônios Aferentes/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Neuropatias Diabéticas/diagnóstico , Eletromiografia , Feminino , Teste de Tolerância a Glucose , Humanos , Masculino , Pessoa de Meia-Idade , Condução Nervosa , Estudos Retrospectivos
7.
Diabetes Care ; 24(8): 1448-53, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11473085

RESUMO

OBJECTIVE: To characterize a cohort of patients with neuropathy and impaired glucose tolerance (IGT) but no other identifiable cause of neuropathy. Of patients with diabetes, 10% have peripheral neuropathy at the time of their diagnosis, suggesting that axonal injury may occur early in the course of glucose intolerance. The American Diabetes Association (ADA) revised diagnostic criteria to recognize IGT (a serum glucose between 140 and 200 mg/dl in a 2-h oral glucose tolerance test [OGTT]) as a risk factor for cardiovascular disease independent of development of diabetes. RESEARCH DESIGN AND METHODS: Using revised ADA criteria for diabetes and IGT, we prospectively evaluated 107 sequential patients with idiopathic neuropathy. RESULTS: A total of 13 of the 107 patients had diabetes, whereas 36 (34%) had IGT, nearly three times the prevalence in age-matched control subjects (P < 0.01). OGTT was often elevated, whereas both fasting plasma glucose and HbA(1c) were normal. Comparing patients with diabetes, IGT, or normal OGTT, age and BMI were similar. However, painful sensory symptoms were more common in patients with IGT and diabetes, and family history of neuropathy was significantly more common in normoglycemic patients. Electrodiagnostic findings of axonal injury were less severe in patients with IGT and were more likely to be confined to sensory fibers than in patients with diabetes. CONCLUSIONS: Our results suggest that IGT may cause or contribute to small-fiber neuropathy, which is similar in phenotype to the painful sensory neuropathy commonly encountered in diabetes. Two-hour OGTT is more sensitive than other measures of glucose handling in screening these patients.


Assuntos
Neuropatias Diabéticas/fisiopatologia , Intolerância à Glucose/epidemiologia , Neuralgia/complicações , Neuralgia/fisiopatologia , Doenças do Sistema Nervoso Periférico/complicações , Doenças do Sistema Nervoso Periférico/fisiopatologia , Adulto , Idoso , Arsênio/urina , Glicemia/metabolismo , Índice de Massa Corporal , Doenças Cardiovasculares/epidemiologia , Neuropatias Diabéticas/epidemiologia , Eletromiografia , Teste de Tolerância a Glucose , Hemoglobinas Glicadas/análise , Humanos , Chumbo/urina , Mercúrio/urina , Pessoa de Meia-Idade , Condução Nervosa , Neuralgia/sangue , Doenças do Sistema Nervoso Periférico/sangue , Prevalência , Estudos Prospectivos , Fatores de Risco
8.
Artigo em Inglês | MEDLINE | ID: mdl-11465931

RESUMO

BACKGROUND: The progressive loss of function affects the quality of life of the ALS patient. Quality of life depends on a spectrum of factors. Available instruments for assessment include questionnaires developed for generic illness-related disabilities and ALS-specific questionnaires that focus on function. METHODS: Comparisons were made between two ALS-specific questionnaires (ALS Functional Rating Scale and SIP/ALS-19) and a generic instrument (Short Form-12) given to 1,513 patients from the (North American) ALS Patient Care Database. RESULTS: The SIP/ALS-19 correlates well with the ALS Functional Rating Scale and less well with the Short Form-12. CONCLUSIONS: The SIP/ALS-19 can be used as an effective surrogate for the ALS Functional Rating Scale, with the advantage that the SIP/ALS-19 also includes questions that encompass the psychological and social domains of quality of life.


Assuntos
Nível de Saúde , Doença dos Neurônios Motores/diagnóstico , Qualidade de Vida , Perfil de Impacto da Doença , Atividades Cotidianas/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Avaliação da Deficiência , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Doença dos Neurônios Motores/psicologia , Psicometria
9.
J Neurol Sci ; 184(1): 51-5, 2001 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-11231032

RESUMO

We report the analysis of a battery of secondary electrophysiologic measurements to assess the progression of amyotrophic lateral sclerosis (ALS) in a two center, six month, double-blind, three arm trial comparing branched chain amino acids to L-threonine with pyridoxal 5-phosphate to placebo. The endpoint measurements were chosen to separately assess the effects of lower motor neuron loss and collateral reinnervation. For tests of inter-center reliability, we found no differences that could not be readily explained by variations in electrophysiologic testing techniques. Since the drug study was negative for the primary endpoint measure (muscle strength), we combined data from both centers and the three treatment arms. For measures of progression, all measures changed in the expected direction during the 6 months of the trial. We conclude that a battery of electrophysiologic measures can be used in a multicenter ALS drug trial to provide information on changes in lower motor neuron numbers and the effects of collateral reinnervation.


Assuntos
Esclerose Lateral Amiotrófica/tratamento farmacológico , Aminoácidos de Cadeia Ramificada/uso terapêutico , Esclerose Lateral Amiotrófica/patologia , Progressão da Doença , Método Duplo-Cego , Eletrofisiologia , Determinação de Ponto Final , Humanos , Neurônios Motores/fisiologia , Reprodutibilidade dos Testes
10.
Neurology ; 56(4): 445-9, 2001 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-11222785

RESUMO

OBJECTIVE: To determine the efficacy of IV immunoglobulin (IVIg) given patients with untreated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: A randomized, double-blind, multicenter, investigator-initiated study compared IVIg (Aventis Behring LLC, King of Prussia, PA) with placebo (5% albumin). On days 1, 2, and 21, IVIg (1 g/kg) or placebo was given. The primary outcome measure was the change in muscle strength from baseline to day 42, using the average muscle score (AMS). Secondary outcome measures included change from baseline AMS at days 10 and 21, the Hughes' functional disability scale, forced vital capacity (FVC), and nerve conduction studies (NCS) of four motor nerves (median, ulnar, peroneal, and tibial). RESULTS: The patients (n = 33) were randomized. Of these, 30 (14 women, 16 men, aged 54 +/- 20 years, range 13 to 82) received IVIg and 23 were given placebo (12 women, 11 men, aged 50 +/- 18 years, range 23 to 73). Baseline AMS values of the groups were similar (IVIg 7.06 +/- 1.31 versus placebo 7.28 +/- 1.18, p = 0.53). There were two dropouts in placebo group and one in the IVIg group. Mean AMS improved at day 42 comparing IVIg with placebo (0.63 versus -0.1, p = 0.006). Improved strength was seen by day 10. The placebo group lost strength over this same interval. In the IVIg, 11 subjects improved by the functional disability scale; none worsened. This differed (p = 0.019) from those in the placebo-treated group (two improved, two got worse, remainder unchanged). Forced vital capacity did not improve with IVIg treatment. IVIg improved ulnar motor distal latency (p = 0.005), tibial distal compound muscle amplitude (p = 0.003), and peroneal nerve conduction velocity (p = 0.03). CONCLUSIONS: IVIg improves strength in patients with untreated CIDP by day 10 with continued benefit through day 42; more than one third improve by at least a functional grade on a disability scale. This study provides data supporting IVIg as the initial treatment for CIDP.


Assuntos
Imunoglobulinas Intravenosas/uso terapêutico , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Feminino , Humanos , Imunoglobulinas Intravenosas/efeitos adversos , Masculino , Pessoa de Meia-Idade , Condução Nervosa/fisiologia , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/fisiopatologia , Fatores de Tempo
12.
Neurol Clin ; 18(3): 681-94, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10873238

RESUMO

The effects of several substances known to produce peripheral neuropathy are reviewed, as are the criteria espoused to be useful in establishing their neurotoxicity. Included is a description of systemic and neurologic symptoms and signs important in identification of the neurotoxic disorder, and a description of the resultant electrodiagnostic abnormalities.


Assuntos
Síndromes Neurotóxicas/etiologia , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Animais , Eletrodiagnóstico , Humanos , Exame Neurológico , Síndromes Neurotóxicas/diagnóstico , Neurotoxinas/efeitos adversos , Neurotoxinas/classificação , Doenças do Sistema Nervoso Periférico/diagnóstico , Sensibilidade e Especificidade
13.
Ann Neurol ; 47(2): 152-61, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10665485

RESUMO

Rigid spine syndrome is a term first proposed by Dubowitz to describe a subset of patients affected by myopathy with early spinal contractures as a prominent feature. While spinal rigidity is a nonspecific feature, found in Emery-Dreifuss muscular dystrophy and in some congenital myopathies, it is also a prominent feature in a group of patients with merosin-positive congenital muscular dystrophy, where it is generally associated with stable or only slowly progressive weakness and early respiratory insufficiency. Recently, the first locus for congenital muscular dystrophy in association with rigid spine syndrome was mapped to chromosome 1p35-p36 in consanguineous Moroccan, Turkish, and Iranian families. We present here a detailed phenotypic description of the familial syndrome linked to this locus, describing 4 siblings (3 boys and 1 girl) of Northern European-American heritage who are the offspring of a nonconsanguineous marriage. All 4 siblings were affected by hypotonia and prominent neck weakness in infancy, early spinal rigidity, and early scoliosis. After initial improvement, muscle strength stabilizes or slowly declines, and skeletal deformities and respiratory insufficiency supervene. Muscle biopsy in an affected child at age 9 months revealed minimal, nonspecific myopathic changes, leading to a diagnosis of "minimal change myopathy." Muscle biopsy in his sibling, at the age of 14 years, revealed chronic and severe myopathic (dystrophic) changes, with normal staining for laminin-2 and for proteins of the dystrophin-glycoprotein complex. A possible explanation for these biopsy findings is that magnetic resonance imaging of the thighs reveals stereotyped selective muscle involvement, with the selectivity more pronounced early in the disease course followed by widespread muscular signal abnormalities in the late stages of the disease. In this family, linkage to the chromosome 1p rigid spine syndrome locus (RSMD1) is supported by maximum LOD scores for several markers of 1.81 at theta = 0, representing the maximum statistical power possible for this family. In combination with the previous report, this syndrome is linked to the RSMD1 locus with a summated maximum LOD score of 6.29, and analysis of recombination events in our family narrows the previously reported RSMD1 locus to 3 centiMorgans.


Assuntos
Distrofias Musculares/congênito , Distrofias Musculares/complicações , Doenças da Coluna Vertebral/complicações , Adolescente , Alelos , Criança , Mapeamento Cromossômico , Feminino , Ligação Genética , Genótipo , Homozigoto , Humanos , Escore Lod , Imageamento por Ressonância Magnética , Masculino , Músculo Esquelético/patologia , Distrofias Musculares/diagnóstico , Distrofias Musculares/genética , Fenótipo , Síndrome
14.
Curr Opin Neurol ; 12(5): 581-8, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10590895

RESUMO

Amyotrophic lateral sclerosis is a neurodegenerative disease with unknown pathogenesis. It is a relatively common disorder of adults (2-4 per 100,000 incidence) and leads to death from respiratory failure. There is no cure at this time, and available treatment and management can at best extend survival to a modest degree. Increasing our understanding of the pathogenesis of this disease is essential to the development of more effective treatments. The level of research interest is very high, and yearly reviews of the literature are helpful in assessing progress.


Assuntos
Esclerose Lateral Amiotrófica/etiologia , Esclerose Lateral Amiotrófica/tratamento farmacológico , Esclerose Lateral Amiotrófica/fisiopatologia , Animais , Modelos Animais de Doenças , Humanos , Neurônios Motores/fisiologia , Caracteres Sexuais
15.
Muscle Nerve ; 22(9): 1244-8, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10454721

RESUMO

Quantitative EMG (QEMG) is a useful technique in the evaluation of neuromuscular disease. Manual waveform measurements have been replaced by automated computer-based measurements, but there is no uniformity in computer algorithms used to make waveform measurements. We compared QEMG measurements made by algorithms in two commercially available EMG machines with manual measurements. Motor unit action potentials (MUAPs) were simultaneously fed into the two machines and analyzed using QEMG default settings and automatic waveform marking. The averaged MUAPs were also manually marked. The two algorithms and manual marking did not differ significantly for MUAP amplitude. There were significant differences between algorithms for duration and number of phases. Our study indicates that, although automated algorithms make QEMG more practical, visual inspection, and remarking of each MUAP if needed, is necessary before making clinical judgments from the data.


Assuntos
Eletromiografia/métodos , Modelos Neurológicos , Neurônios Motores/fisiologia , Potenciais de Ação , Algoritmos , Humanos
17.
Scand J Work Environ Health ; 25(2): 115-24, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10360466

RESUMO

OBJECTIVES: The goal of this study was to evaluate the concordance between various clinical screening procedures for carpal tunnel syndrome. METHODS: The subject population consisted of 824 workers from 6 facilities. The evaluated procedures included bilateral sensory nerve conduction testing, physical examinations, and symptom surveys, including hand diagrams. The agreement between the outcomes of various combinations of these procedures was assessed by determining the kappa coefficient. RESULTS: There was relatively poor overlap between the reported symptoms, the physical examination findings, and the electrodiagnostic results consistent with carpal tunnel syndrome. Overall, only 23 out of 449 subjects (5%) with at least 1 positive finding met all 3 criteria (symptoms, physical examination findings, and electrophysiological results consistent with carpal tunnel syndrome) for the dominant hand. The screening procedures showed poor or no agreement with kappa values ranging between 0.00 and 0.18 for all the case definitions evaluated for carpal tunnel syndrome. CONCLUSIONS: The poor overlap between the various screening procedures warns against the use of electrodiagnostic findings alone without the symptom presentation being considered. The results of this study also point to a need for the further development and evaluation of methods for detecting carpal tunnel syndrome.


Assuntos
Síndrome do Túnel Carpal/diagnóstico , Eletrodiagnóstico/normas , Programas de Rastreamento/métodos , Doenças Profissionais/diagnóstico , Exame Físico/normas , Inquéritos e Questionários/normas , Adulto , Síndrome do Túnel Carpal/epidemiologia , Síndrome do Túnel Carpal/fisiopatologia , Estudos Transversais , Métodos Epidemiológicos , Feminino , Lateralidade Funcional , Humanos , Masculino , Condução Nervosa , Doenças Profissionais/epidemiologia , Doenças Profissionais/fisiopatologia , Vigilância da População/métodos , Reprodutibilidade dos Testes
19.
Neurology ; 52(2): 317-20, 1999 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-9932950

RESUMO

OBJECTIVE: To evaluate the utility of "clinic room" case presentation in the ambulatory care setting. BACKGROUND: Neurology is increasingly an outpatient specialty. The transition from ward to clinic presents challenges for student and resident education. Interaction between attending physician and trainee is limited by busy patient schedules. New educational strategies must be developed to address the particular challenges of the outpatient clinic. One strategy to increase the quality and length of attending-trainee interaction is case presentation in the patient's presence. METHODS: The authors randomized 100 patients seen in an academic neuromuscular clinic to presentation in a conference room or clinic room. In the latter, all interaction between the trainee and attending occurred in the patient's presence. The attending recorded the time spent with the trainee and patient. The patient was asked to complete a survey and provide certain demographic information. RESULTS: The two groups were similar demographically. Time spent by the attending physician was similar between the two settings. Although there was no difference in patient satisfaction, those randomized to clinic room presentation were significantly more likely (p < 0.002) to feel their questions were answered adequately. There were trends toward these patients feeling less embarrassed, feeling that they were treated respectfully, and feeling that adequate time was spent with them. CONCLUSIONS: Although clinic room presentation does not save attending time, it allows for a more dynamic and intensive interaction among teacher, student, and patient.


Assuntos
Assistência Ambulatorial/métodos , Neurologia/educação , Ambulatório Hospitalar , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Garantia da Qualidade dos Cuidados de Saúde
20.
Expert Opin Investig Drugs ; 8(6): 885-902, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15992138

RESUMO

Motor neurone disease (MND) is a group of progressive neurodegenerative disorders that cause disability from weakness and lead to death from respiratory failure. The pathophysiology of the several forms of MND is unknown, but recent advances have led to clinical trials of therapeutic agents based on an improved understanding of the pathologic processes. The design of clinical trials in MND is challenging, because an effective drug cannot restore strength, but rather slow the rate of progression. Measurement of progression poses difficulties, and an optimum end-point measure has not been determined. This article will include the clinical features of MND, present the leading hypotheses about causes as they relate to drug therapy, discuss factors to consider in selecting informative end-point measures, and will review past and current drug trials.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...